1. The plaintiff's claim is dismissed.

2. The costs of lawsuit shall be borne by the Plaintiff.

1. Basic facts

(a) The name of the invention claimed in this case: The date of filing of the plaintiff/priority claim / the filing date of the divisional application / the application number: C/D/E claims on January 27, 2010 (amended by the correction of December 28, 2017) 【 Claim 1’s chemical compound or its pharmaceutically permissible salt, lamivineidine or its pharmaceutically permitted salt: (a) combination for treating HIV infection (hereinafter referred to as “instant Claim 1”). 【The Claim 2 through 9 omitted technical field and background technology / 001 human immunodeficiency (HIV), namely, the characteristics of immunodeficiency-cell infection with an incidental opportunity to infection, and the characteristics of immunodeficiency et al. al. (HIV) damage from strophyphyymosis and strophymosis-related infection, and the characteristics of the immunodeficiency (HIV)'s strophymosis et al.

HIV is Letroviz.

The transition from the RNA to the DNA is achieved through the effects of Filial Efficacy.

A compound that suppresss the function of the calendar shall restrain the reproduction of HIV from the infected cell.

Such a compound is useful in humans to prevent or treat HIV infections.

【002】 In addition to CD4, HIV requires a joint body for entry into a sponary cell.

Kink’s accommodation functions as a joint body for HIV together with CD4.

CXCR4 andCCR5 were confirmed as a state joint body for HIV-1.

CCR5 acts as a major co-receptor for convergence and entry into large-cell cells-ditronomic HIV within a host cell.

These cares are considered to play an essential role in the establishment and sowing of HIV infections.

Therefore,CCR5 route clause is useful as active treatment for HIV.